Ezevi Tablet (Ezetimibe)
Ezetimibe 10mg
Tablet · Prescription medication
Hanpoong Pharmaceutical Co., Ltd.
MFDS item code 201905472 · Approved 2019.08.01
This product's status changed to Expired on 2024.08.01. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of hypercholesterolemia, mixed hyperlipidemia, and sitosterolemia
This medication is used for various dyslipidemias including primary hypercholesterolemia, homozygous familial hypercholesterolemia, and homozygous sitosterolemia. It helps lower high cholesterol, LDL cholesterol, and apolipoprotein B levels in patients and can be administered as a dietary adjunct alone or in combination with other lipid-lowering agents. Additionally, it plays an important role in improving lipid control and cholesterol levels in patients with an increased risk of atherosclerotic vascular disease. It is necessary to identify and treat other secondary causes prior to administration, and regular lipid tests should be conducted to monitor therapeutic effects. This medication is effectively used in comprehensive management of dyslipidemia, improving blood lipid levels.
A standard cholesterol-lowering diet should be continued during treatment with this medicine. The recommended dose of this medicine is 10 mg once daily, without regard to meals. When administered concomitantly with an HMG-CoA reductase inhibitor (in patients with primary hypercholesterolemia), initiate this medicine concomitantly at the recommended starting dose of the HMG-CoA reductase inhibitor. If the patient is already receiving a high dose of an HMG-CoA reductase inhibitor, administer this medicine concomitantly while maintaining the HMG-CoA reductase inhibitor dose. When this medicine is administered concomitantly with fenofibrate (in patients with mixed hyperlipidemia), administer it with fenofibrate 160mg once daily or 200mg once daily (see Precautions for Use, 4. General Precautions). Administration to patients with hepatic impairment No dose adjustment is required in patients with mild hepatic impairment; however, administration of this medicine is not recommended in patients with moderate to severe hepatic impairment (see Precautions for Use, 2. Administration with Caution in the Following Patients). Administration to patients with renal failure No dose adjustment is required in patients with renal failure. Administration to elderly patients No dose adjustment is required in elderly patients. Concomitant administration with bile acid sequestrants This medicine should be administered at least 2 hours before or at least 4 hours after administration of a bile acid sequestrant (see Precautions for Use, 5. Interactions).
This medication should not be used in patients who are allergic to its components. Avoid combining this medication with certain cholesterol-lowering agents in patients with severely impaired liver function or unexplained elevations in liver enzyme levels. The use of this medication in pregnant or breastfeeding women is prohibited; therefore, women who may become pregnant need to exercise caution. Patients with severe liver dysfunction may experience increased exposure to this medication, leading to unexpected side effects; thus, its use is not recommended. While this medication is generally safe, side effects such as headache, abdominal pain, and diarrhea may occur, and rarely, muscle pain or elevated liver enzyme levels have been reported. When used in combination with other cholesterol-lowering agents, liver function and muscle status should be regularly monitored, and any symptoms of muscle pain or weakness should be reported to a physician immediately. Patients with severe kidney disease should also exercise caution when using this medication, particularly when combined with other drugs, following the physician's instructions. This medication is recommended for use in children aged 6 years and older, and it can also be safely used in the elderly, although individual sensitivity may vary. Women who are pregnant or breastfeeding should carefully consider the potential risks and benefits of using this medication, and it is advisable to avoid use during breastfeeding if possible. In case of overdose, as there are no specific antidotes, it is important to receive appropriate treatment based on symptoms. This medication should be kept out of reach of children, and transferring it to another container should be avoided.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it should be stored in a tightly closed container. It is advisable to maintain the storage temperature between 1°C and 30°C.
White to almost white rectangular tablets
30 tablets/PTP [(10 tablets/PTPX3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Ezetimibe 10mg
Tablet · Prescription medication
Hanpoong Pharmaceutical Co., Ltd.

Ezetimibe 10mg
Tablet · Prescription medication
Korea Organon Co., Ltd.

Ezetimibe 10mg
Tablet · Prescription medication
Hanmi Pharmaceutical Co., Ltd.

Ezetimibe 10mg
Tablet · Prescription medication
Genewon Science Co., Ltd.

Ezetimibe 10mg
Tablet · Prescription medication
Shin Il Pharmaceutical Co., Ltd.

Ezetimibe 10mg
Tablet · Prescription medication
Korea Hutech Pharmaceutical Co., Ltd.

Ezetimibe 10mg
Tablet · Prescription medication
Hwanin Pharmaceutical Co., Ltd.

Ezetimibe 10mg
Tablet · Prescription medication
Jinyang Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.